Women with polyendocrine metabolic ovarian syndrome (PMOS) in the UK should get diagnosed sooner and be offered an annual review of their condition, according to new guidance from NICE. Draft guidance ...
The Memo deal falls into the latter camp, as while the BK polyomavirus is common, it usually remains inactive in the body and only causes problems in people with a weakened immune system, including ...
Tregzi is the second cell therapy to be approved by the FDA for use in the context of managing GVHD in HSCT patients, albeit ...
As the US relaxes an export ban on Anthropic's advanced AI tools, the company formally launched Claude Science, an AI ...
Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder (SAD), cratering ...
Patients with newly diagnosed mantle cell lymphoma (MCL) could avoid chemotherapy with a regimen based on BeOne Medicines' ...
Sanofi is preparing to expand the use of its Pompe therapy Nexviazyme, currently approved only for late-onset cases of the ...
Members of the China Select Committee in the US House have launched a national security investigation into a number of big pharma companies, asking for details of their use of clinical trial sites in ...
Eli Lilly, Regeneron, and five other companies have been selected to take part in the FDA's PreCheck pilot programme, designed to make it easier and quicker to set up US manufacturing facilities. The ...
Unicycive Therapeutics' hopes of getting FDA approval of its drug for hyperphosphataemia in patients with chronic kidney disease (CKD) who need dialysis have been knocked back again. The US regulator ...
Positive mid-stage results with Apogee Therapeutics' IL-13 inhibitor APG777 in atopic dermatitis have driven the company's shares up around 20%, as it prepares for a phase 3 programme. The 16-week ...
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results